Key Developments: Bayer AG (BAYZF.PK)

BAYZF.PK on OTC Markets Group

137.65USD
11 Jul 2014
Price Change (% chg)

$0.47 (+0.34%)
Prev Close
$137.18
Open
$137.65
Day's High
$137.65
Day's Low
$137.65
Volume
181
Avg. Vol
697
52-wk High
$145.00
52-wk Low
$108.85

Search Stocks

Latest Key Developments (Source: Significant Developments)

Bayer HealthCare to evaluate Riociguat in new indication
Monday, 2 Jun 2014 08:00pm EDT 

Bayer AG:Bayer HealthCare starts a randomized double-blind, placebo-controlled Phase IIb study with Riociguat in Patients with Symptomatic Pulmonary HypErtension associated with Idiopathic Interstitial Pneumonias.RISE-IIP study is designed to investigate the efficacy and safety of riociguat in patients with symptomatic pulmonary hypertension associated with idiopathic interstitial pneumonia.RISE-IIP trial will be carried out at more than 50 sites in 11 countries and will enroll about 120 patients.  Full Article

Merck & Co Inc announces sale of consumer care business to Bayer AG for $14.2 bln
Tuesday, 6 May 2014 06:00am EDT 

Merck & Co Inc:Enters into definitive agreement to sell its Merck Consumer Care (MCC) business to Bayer AG for $14.2 bln.Bayer AG will acquire Merck's existing OTC business, including global trademark and prescription rights for Claritin and Afrin.Merck expects to close sale of MCC in second half of 2014.Morgan Stanley & Co. LLC acted as financial advisor to Merck, and Fried Frank Harris Shriver & Jacobson LLP and Morgan Lewis & Bockius LLP acted as legal counsel in connection with transaction.J.P. Morgan advised Merck with ongoing portfolio assessment leading up to transaction.Also worldwide clinical development collaboration with Bayer to market and develop its portfolio of soluble guanylate cyclase (sGC) modulators.This includes Bayer's Adempas (riociguat), the first member of this novel class of compounds.Collaboration also includes clinical development of vericiguat (BAY102), which is currently in Phase 2 trials for worsening heart failure, as well as opt-in rights for other early-stage sGC compounds in development at Bayer.Merck will in turn make available its early-stage sGC compounds under similar terms.  Full Article

Bayer AG confirms FY 2014 outlook - Reuters
Monday, 28 Apr 2014 02:17am EDT 

Bayer AG:Confirms FY 2014 outlook for low to medium single digit percentage rise in adjusted EBITDA - Reuters.Confirms FY 2014 outlook for currency adjusted sales of around 41-42 billion euros.FY 2014 revenue estimate 41.906 billion euros - Thomson Reuters I/B/E/S.  Full Article

Bayer AG's Bayer HealthCare launches eight new products to treat flea and tick infestations
Wednesday, 12 Mar 2014 08:07am EDT 

Bayer AG:Bayer HealthCare LLC Animal Health division launches eight new flea and/or tick treatment and control solutions to be sold at pet specialty retail stores, adding to its existing line of flea and/or tick prevention and treatment products.Four of these products - advantage treatment spray for dogs, advantage treatment Spray for cats, Advantage Treatment Shampoo for dogs, and Advantage Treatment Shampoo for cats - provide pet owners with an array of pest treatment options.Bayer's new Advantage Household Spot & Crevice Spray, Advantage Carpet & Upholstery Spot Spray, and Advantage Household Fogger kill indicated pests in the home, while Advantage Yard & Premise Spray kills pests in yard and around the house.  Full Article

Bayer's Aviator resolves compulsory acquisition of Algeta
Friday, 7 Mar 2014 10:40am EST 

Algeta ASA:Says Bayer AG's Aviator Acquisition AS resolves compulsory acquisition (squeeze-out) of all outstanding shares of Algeta not owned by Aviator with effect from end of trading on Oslo Stock Exchange March 7.Aviator offers 362 Norwegian crowns per share.Payment of the compulsory offer will be made on March 17.  Full Article

Bayer completes voluntary takeover offer for Algeta ASA made through subsidiary Aviator Acquisition AS and intends to file for delisting of Algeta shares from Oslo Stock Exchange
Thursday, 6 Mar 2014 02:30am EST 

Algeta ASA:Says The Bayer Group has completed the voluntary takeover offer forAlgeta ASA made through its wholly owned subsidiary Aviator Acquisition AS (Bayer).Says payment of the offer price has been made to Algeta's shareholders who accepted the takeover offer and, at the same time, the 43,131,641 tendered shares have been transferred to Bayer.Says as a result, Bayer holds 98.2 pct of the shares and voting rights in Algeta.Says Bayer intends to initiate a compulsory acquisition process in order to acquire the remaining shares of minority shareholders in Algeta in the coming days.Says Bayer is offering 362 Norwegian crowns per share, equal to the offer price in Bayer's voluntary takeover offer.Says Bayer intends to file for delisting of the Algeta shares from the Oslo Stock Exchange (OSE).  Full Article

Bayer AG gives FY 2014 sales guidance in line with analysts' estimates - Conference Call
Friday, 28 Feb 2014 01:30pm EST 

Bayer AG:Sees FY 2014 sales organically by about 5 pct.Company reported sales of 40.157 bln euro in FY 2013.FY 2014 revenues of 42.350 bln euro - Thomson Reuters I/B/E/S.  Full Article

Algeta announces results of voluntary takeover bid made by Bayer's subsidiary
Wednesday, 26 Feb 2014 04:06am EST 

Algeta ASA:Says Bayer has received acceptances for the voluntary takeover offer made through Aviator Acquisition AS for a total of about 42,731,347 shares, representing about 97.28 pct of Algeta's share capital.All regulatory approvals required for completion of the proposed acquisition have been obtained.The transfer of shares to Bayer and the payment of the offer price will take place in the coming days but no later than March 12.Bayer intends to initiate a compulsory acquisition process with the aim of becoming the sole shareholder of Algeta and to file for delisting of the Algeta shares from the Oslo Stock Exchange.Bayer expects to complete the acquisition in Q1 2014.  Full Article

Bayer AG to propose dividend for fiscal year 2013
Tuesday, 25 Feb 2014 07:00pm EST 

Bayer AG:Will propose dividend of 2.10 euro per share for FY 2013.FY 2012 dividend was of 1.90 euro per share.Total dividend payment would amount to 1,737 million euro.  Full Article

Bayer AG extends offer period for voluntary offer to acquire all shares in Algeta ASA
Monday, 24 Feb 2014 02:45am EST 

Algeta ASA:Says Bayer AG is extending the offer period for the voluntary offer to acquire all the shares in Algeta ASA, made through its wholly owned subsidiary Aviator Acquisition AS (hereinafter referred to as Bayer), by two days to Feb. 26 at 09:00 CET.Says all other terms and conditions of the offer remain unchanged.Says Bayer is offering 362 Norwegian crowns in cash per Algeta share.Says that as of Feb. 24 at 07.40 CET, Bayer had received acceptances and pre-acceptances of the offer for about 40,485,490 shares, representing about 92.17 pct of Algeta's share capital.Says the cash offer of 362 Norwegian crowns for each Algeta share represents an equity value of 17.6 bln Norwegian crowns (2.1 bln euros) and an enterprise value of 16.2 bln Norwegian crowns (1.9 bln euros).  Full Article

Search Stocks